Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Differential effects of amnion and chorion membrane extracts on osteoblast-like cells due to the different growth factor composition of the extracts.

Go YY, Kim SE, Cho GJ, Chae SW, Song JJ.

PLoS One. 2017 Aug 10;12(8):e0182716. doi: 10.1371/journal.pone.0182716. eCollection 2017.

2.

Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women.

Liu M, Xing LQ.

Oncol Lett. 2017 Aug;14(2):1561-1567. doi: 10.3892/ol.2017.6335. Epub 2017 Jun 7.

3.

Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells.

Wang Z, Tan Y, Yu W, Zheng S, Zhang S, Sun L, Ding K.

Int J Biol Sci. 2017 Feb 25;13(3):339-348. doi: 10.7150/ijbs.17680. eCollection 2017. Review.

4.

Fibroblast growth factors, old kids on the new block.

Li X, Wang C, Xiao J, McKeehan WL, Wang F.

Semin Cell Dev Biol. 2016 May;53:155-67. doi: 10.1016/j.semcdb.2015.12.014. Epub 2016 Jan 6. Review.

5.

PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR.

Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JN, Chen ZS.

Acta Pharm Sin B. 2014 Jun;4(3):202-7. doi: 10.1016/j.apsb.2014.02.003. Epub 2014 Mar 29.

6.

Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing.

Gong X, Lin C, Cheng J, Su J, Zhao H, Liu T, Wen X, Zhao P.

PLoS One. 2015 Jun 19;10(6):e0130348. doi: 10.1371/journal.pone.0130348. eCollection 2015.

7.

Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.

Li H, Li H, Qu H, Zhao M, Yuan B, Cao M, Cui J.

Cancer Cell Int. 2015 May 13;15:52. doi: 10.1186/s12935-015-0196-y. eCollection 2015.

8.

Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.

D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1237-1245. doi: 10.1007/s00280-015-2751-6. Epub 2015 Apr 24.

9.

Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.

Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL.

AAPS J. 2015 Jan;17(1):268-76. doi: 10.1208/s12248-014-9703-7. Epub 2014 Nov 26.

10.

Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.

D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, Carella N, Messa C, Cavallini A, Carr BI.

BMC Cancer. 2014 May 21;14:351. doi: 10.1186/1471-2407-14-351.

11.

A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.

Borges S, Döppler HR, Storz P.

Breast Cancer Res Treat. 2014 Feb;144(1):79-91. doi: 10.1007/s10549-014-2857-2. Epub 2014 Feb 8.

12.

Positional information is reprogrammed in blastema cells of the regenerating limb of the axolotl (Ambystoma mexicanum).

McCusker CD, Gardiner DM.

PLoS One. 2013 Sep 27;8(9):e77064. doi: 10.1371/journal.pone.0077064. eCollection 2013.

13.

Targeting fibroblast growth factor pathways in prostate cancer.

Corn PG, Wang F, McKeehan WL, Navone N.

Clin Cancer Res. 2013 Nov 1;19(21):5856-66. doi: 10.1158/1078-0432.CCR-13-1550. Epub 2013 Sep 19. Review.

14.

Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells.

Ikeda R, Vermeulen LC, Lau E, Jiang Z, Kavanaugh SM, Yamada K, Kolesar JM.

Oncol Lett. 2011 Jan;2(1):91-94. Epub 2010 Oct 19.

15.

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22.

16.

Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Martinez-Rivera M, Siddik ZH.

Biochem Pharmacol. 2012 Apr 15;83(8):1049-62. doi: 10.1016/j.bcp.2011.12.026. Epub 2011 Dec 26. Review.

17.

Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.

Costa-Pereira AP, Bonito NA, Seckl MJ.

Am J Cancer Res. 2011;1(6):806-16. Epub 2011 Jun 22.

18.

A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.

Carmo CR, Lyons-Lewis J, Seckl MJ, Costa-Pereira AP.

PLoS One. 2011;6(5):e19861. doi: 10.1371/journal.pone.0019861. Epub 2011 May 20.

19.

Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.

Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, Humbert M, Eddahibi S, Guignabert C.

Am J Respir Cell Mol Biol. 2011 Aug;45(2):311-22. doi: 10.1165/rcmb.2010-0317OC. Epub 2010 Oct 29.

20.

Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction.

Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y.

Int J Cardiol. 2011 Nov 3;152(3):307-13. doi: 10.1016/j.ijcard.2010.07.024. Epub 2010 Aug 2.

Supplemental Content

Support Center